DEFA14A: Recursion Pharmaceuticals Announces Date for Q3 2024 Results and Investor Update Call Post-Exscientia Merger

Recursion Pharmaceuticals will release its Q3 2024 financial results on November 6th and plans an investor update call on November 20th, following the anticipated close of its merger with Exscientia.

Summary

• Recursion Pharmaceuticals will announce its Q3 2024 business updates and financial results on November 6th, 2024, after market close.
• The company will not hold its usual earnings call for the third quarter.
• Instead, Recursion plans to host an investor update call on November 20th, 2024, after the expected completion of the proposed business combination with Exscientia.
• The update call will be broadcast live on Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts, with opportunities for questions.
• The announcement also reiterates information about the proposed business combination with Exscientia plc, initially announced on August 8, 2024.
• The company directs investors and security holders to read the definitive joint proxy statement filed with the SEC on October 10, 2024, for detailed information about the proposed business combination.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive, reflecting the clear communication of upcoming events and the progress towards the Exscientia merger. However, the forward-looking statements and inherent risks in pharmaceutical development temper the overall sentiment.

Positives

• The company is providing a clear timeline for its Q3 2024 results and a post-merger update.
• The investor update call will be accessible via multiple online platforms, increasing accessibility for stakeholders.

Negatives

• The absence of a traditional earnings call for Q3 might limit immediate interaction with analysts and investors before the merger update.

Risks

• The investor update call is contingent on the successful and timely closing of the Exscientia merger, which is subject to various risks and uncertainties.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including challenges in pharmaceutical research and development, financing, and regulatory approvals.

Future Outlook

The company anticipates closing the proposed business combination with Exscientia and hosting an investor update call on November 20, 2024, contingent on the merger's completion.

Industry Context

The announcement reflects a trend in the TechBio industry where companies are combining technology and biology to accelerate drug discovery, as exemplified by Recursion's proposed merger with Exscientia.

Stakeholder Impact

• Shareholders will receive updates on the company's financial performance and the progress of the Exscientia merger.
• Employees may be affected by the integration of the two companies following the merger.
• The merger could impact the company's ability to advance its drug discovery programs and deliver new medicines to patients.

Next Steps

• Recursion will release its Q3 2024 financial results on November 6th, 2024.
• The company expects to close the business combination with Exscientia.
• Recursion plans to host an investor update call on November 20th, 2024, after the anticipated close of the merger.

Key Dates

Keywords

Recursion Pharmaceuticals, Exscientia, merger, Q3 2024, financial results, investor update, business combination, TechBio, drug discovery